

# Mathias Vormehr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1335400/publications.pdf>

Version: 2024-02-01

27  
papers

8,459  
citations

471371

17  
h-index

580701

25  
g-index

37  
all docs

37  
docs citations

37  
times ranked

13207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
2	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
3	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
4	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583
5	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. <i>Nature</i> , 2020, 586, 594-599.	13.7	1,520
6	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020, 183, 818-834.e13.	13.5	287
7	A liposomal RNA vaccine inducing neoantigen-specific CD4 <sup>+</sup> T cells augments the antitumor activity of local radiotherapy in mice. <i>Oncolmmunology</i> , 2020, 9, 1771925.	2.1	32
8	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. <i>Frontiers in Oncology</i> , 2020, 10, 1195.	1.3	94
9	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> , 2020, 585, 107-112.	13.7	526
10	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. <i>Oncolmmunology</i> , 2020, 9, 1758004.	2.1	17
11	Personalized Neo-Epitope Vaccines for Cancer Treatment. <i>Recent Results in Cancer Research</i> , 2020, 214, 153-167.	1.8	9
12	561...DuoBody®-PD-L1-4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation. , 2020, , .		1
13	A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. <i>BMC Cancer</i> , 2019, 19, 914.	1.1	1
14	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. <i>Annual Review of Medicine</i> , 2019, 70, 395-407.	5.0	54
15	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. <i>Oncolmmunology</i> , 2019, 8, e1601480.	2.1	18
16	A non-functional neopeptide specific CD8 <sup>+</sup> T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . <i>Oncolmmunology</i> , 2019, 8, 1553478.	2.1	16
17	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. <i>Methods in Molecular Biology</i> , 2017, 1499, 223-236.	0.4	9
18	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , 2017, 547, 222-226.	13.7	1,806

#	ARTICLE	IF	CITATIONS
19	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. <i>Clinical Cancer Research</i> , 2016, 22, 1885-1896.	3.2	128
20	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. <i>Nature</i> , 2016, 534, 396-401.	13.7	1,243
21	Mutanome directed cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 14-22.	2.4	55
22	Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. , 2016, , .		3
23	Abstract CT022: IVACÂ® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma. , 2016, , .		0
24	Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms. , 2016, , .		0
25	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. <i>Journal of Immunology Research</i> , 2015, 2015, 1-6.	0.9	27
26	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <i>Nature</i> , 2015, 520, 692-696.	13.7	1,030
27	Abstract 5012: Establishment of a transplantable, NY-BR-1 expressing breast cancer model in HLA-transgenic mice. , 2015, , .		0